The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma. [electronic resource]
Producer: 20120618Description: 58-68 p. digitalISSN:- 1744-6880
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Pharmacological
- Cytidine Deaminase -- genetics
- Deoxycytidine -- administration & dosage
- Deoxycytidine Kinase -- genetics
- Disease-Free Survival
- Female
- Genetic Association Studies
- Genotype
- Haplotypes
- Humans
- Male
- Mesothelioma -- drug therapy
- Middle Aged
- Neoplasm Staging
- Polymorphism, Single Nucleotide
- Promoter Regions, Genetic
- Retrospective Studies
- Ribonucleoside Diphosphate Reductase
- Treatment Outcome
- Tumor Suppressor Proteins -- genetics
- Gemcitabine
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.